PDL1 and CD38 antigen expression in NSCLC

Torben Plesner

Torben Plesner, MD, from the Vejle Hospital and University of Southern Denmark, Vejle, Denmark, discusses antigen expression in non-small cell lung cancer (NSCLC) at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. Patients with NSCLC that expresses PDL1 tend to have a better response with a PDL1 rather than chemotherapy. Expression of CD38 has been found to be associated with refractoriness, and removal of this antigen improves response to other treatments, such as checkpoint inhibitors. However, there is concern that less expression of CD38 increases resistance to daratumumab, but Dr Plesner explains that it will allow other treatments to come into play, it’s just a matter of finding the right one.

Share this video